Contact

latest entries

Novel Anti-Cancer Compound from Queen's University
genericized drug compound, SW-01, specific for inhibiting the RET receptor tyrosine kinase
miR-9 as target to selectively inhibit glioblastoma tumor stem cell growth offered by Max-Planck-Innovation
targets and suitable for diagnostic purposes
Lilly is seeking opportunities in targeted cancer therapy, predictive biomarkers and novel drug formulations
Palau is seeking late pre-clinical stage NCEs in inflammatory, autoimmune and respiratory diseases
targets and indications in the inflammatory, autoimmune and respiratory fields; patent-protected New Chemical Entities or New Formulation projects
Tumor antigens for use in diagnostic and therapy
Patterns of glioma antigens have been identified, which trigger a B-cell-mediated immune response, especially in patients affected by gliooma.